Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03983733 · ClinicalTrials.gov registry record · NA

PREDICT 2: Personalized Responses to Dietary Composition Trial 2

A NA study, sponsored by Zoe Global Limited.

Completed
Registry status
NA
Development phase
1,139
Enrollment target

NCT03983733: Completed NA study, sponsored by Zoe Global Limited.

NCT03983733 is a NA study that has completed, run by Zoe Global Limited. The registered enrollment target is 1,139 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (19% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03983733, a NA study, has completed, sponsored by Zoe Global Limited.

COMPLETED
Registry status
NA
Development phase
1,139 participants
Enrollment target

Study Summary

Foods in the human diet can affect the development of diseases over time, such as diabetes or heart disease. This is because the amount and types of foods in the diet eat can affect a person's weight, and because different foods are metabolised (processed) by the body in different ways. Scientists have also found that the bacteria in the human gut (the gut microbiome) affect their metabolism, weight and health and that, together with a person's diet and metabolism, could be used to predict appetite and how meals affect the levels of sugar (glucose) and fats (lipids) found in blood after eating. If blood sugar and fat are too high too often for too long, there is a greater chance of developing diseases such as diabetes and cardiovascular disease. The gut microbiome is different in different people. Only 10-20% of the types of bacteria found in the human gut are found in everyone. This might mean that the best diet to prevent disease needs matching to a person's gut microbiome and it might be possible to find personalised foods or diets that will help reduce the chance of developing chronic disease as well as metabolic syndrome. The study investigators are recruiting volunteers aged 18-70 years to take part in a study that aims to answer the questions above. Participants will be asked to consume standardised meals on up to 8 days while wearing glucose monitors (Abbott Freestyle Libre) to measure their blood sugar levels. Participants will also be required to prick their fingers at regular intervals to collect small amounts of blood, and to record their appetite, food, physical activity and sleep using apps and wearable devices. They will be asked to collect a fecal and saliva sample before consuming the standardised meals, and to provide a fasted blood sample at the end of the study period.

Primary Outcome

Species count in fecal sample

Interventions

  • OTHER Dietary Intervention

Trial Details

FieldValue
Enrollment Target 1,139 participants
Start Date 2019-06-10
Est. Completion 2021-12-01
Phase NA
Zoe Global Limited

3 total trials

What the finished NCT03983733 record still lists

NCT03983733 is an interventional study that assigns participants to a tested intervention. Its 1,139 participants enrollment target places it among the larger protocols in the corpus, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (19% lower).

The record links to 0 conditions, and to 1 intervention - of which Dietary Intervention is the first listed.

NCT03983733 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03983733 about?

NCT03983733 is a clinical study titled "PREDICT 2: Personalized Responses to Dietary Composition Trial 2". Foods in the human diet can affect the development of diseases over time, such as diabetes or heart disease. This is because the amount and types of foods in the diet eat can affect a person's weight, and because different foods are metabolised (processed) by the body in different ways. Scientists ...

What is the current status of trial NCT03983733?

This trial is currently completed. It is a NA study. The enrollment target is 1,139 participants. The study started on 2019-06-10. Estimated completion is 2021-12-01.

What interventions are being tested in trial NCT03983733?

The interventions under investigation include: Dietary Intervention (OTHER).

Who is sponsoring clinical trial NCT03983733?

This trial is sponsored by Zoe Global Limited, which has 3 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03983733's enrollment target sits among peer trials

1,139 93rd of 2000 higher than 1,908 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05894967 · 1,140 participants · NA

    Moderators and Mediators of Perceptual Learning

  • NCT06532487 · 1,140 participants · NA

    Addressing Durable Health Disparities Through Critical Time Legal Interventions in Medically Underserved Latinx and Migrant Communities

  • NCT06129864 · 1,145 participants · Phase 3

    A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

  • NCT06676319 · 1,147 participants · Phase 2

    Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03983733, the US trial registry maintained by the National Library of Medicine. NCT03983733 (large enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.